Previous studies have shown that blocking the CD47-SIRPα signal could not only restart phagocytosis but also enhance tumor antigen presentation and activate specific antitumor immune response, reacting in both innate and adaptive immunity (16–18). The gene discussed is CD47; the disease is neoplasm.